March 09, 2026
Novo Nordisk A/S will start selling its GLP-1 medications on Hims & Hers Health Inc.'s platform as part of a deal that resolves the pharmaceutical company's patent infringement lawsuit against the telehealth provider, the companies announced Monday.
February 10, 2026
Rodger D. Smith II and Jeremy A. Tigan of Morris Nichols Arsht & Tunnell LLP represent Novo Nordisk in its challenge against telehealth company Hims & Hers Health Inc.
February 10, 2026
Novo Nordisk's patent infringement suit against telehealth company Hims & Hers over an affordable GLP-1 pill is an escalation in the larger battle between obesity drugmakers and compounding pharmacies.
February 09, 2026
Novo Nordisk AS followed through on Monday in Delaware federal court on a plan it announced last week to sue telehealth company Hims & Hers Health Inc. over its marketing of what Novo Nordisk calls a knockoff version of its GLP-1 medications.